Published on
HCV Guidance
(
https://www.hcvguidelines.org
)
Home
>
Treatment-Naive Genotype 3 Without Cirrhosis
>
Treatment-Naive Genotype 3 Without Cirrhosis
Recommended and alternative regimens listed by pangenotypic, evidence level and alphabetically for:
Treatment-Naive Genotype 3 Patients Without Cirrhosis
RECOMMENDED
DURATION
RATING
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)
a
8 weeks
I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
12 weeks
I, A
a
Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
Last update:
October 24, 2022